<DOC>
	<DOCNO>NCT00548938</DOCNO>
	<brief_summary>The purpose study determine safety efficacy combination Gliadel wafer plus surgery limited field radiation therapy concomitant temozolomide follow temozolomide give extend dose schedule ( metronomic schedule ) patient undergo initial surgery newly-diagnosed high grade glioma .</brief_summary>
	<brief_title>Gliadel Wafer , Temozolomide Radiation Therapy Newly Diagnosed GBM</brief_title>
	<detailed_description>The patient population Phase II clinical trial patient newly diagnose high-grade glioma undergo initial surgery . Patients receive Surgery + GliadelÂ® wafer implantation + Limited Field Radiation Therapy concomitant daily temozolomide ( 75 mg/m2 ) follow monthly temozolomide give dose ( 75 mg/m2 per day 21 day month . Patients 8 wafer implanted tumor resection cavity ( depend upon size ) maximal tumor resection . Between Study Days 14 45 patient begin standard course post-operative limited field radiation therapy tumor site surround margin . Temozolomide administer concomitantly radiation daily dose 75 mg/m2 daily ( 7 days/week ) beginning later 30 day follow completion radiation therapy 75 mg/m2 daily dose give 21 day month total 18 cycle .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>Men woman , must age 1872 Patients must radiographic evidence cranial magnetic resonance imaging ( MRI ) single , contrastenhancing unilateral supratentorial cerebral tumor suggestive highgrade glioma Surgical treatment within 4 week baseline MRI indicate Karnofsky Performance Score 60 high Patients must pathological diagnosis highgrade ( IV ) malignant glioma Patients must willing use barrier method contraception fertile childbearing potential 2 year wafer implantation counsel regard unknown , potentially harmful , risk embryo fetus treat study Patients prior cytoreductive surgery highgrade glioma ( patient diagnostic stereotactic biopsy eligible ) Patients one focus tumor tumor cross midline assess coronal cranial MRI scan Concomitant significant lifethreatening disease patient could reasonably expect die within first 12 month study Known hypersensitivity reaction temozolomide , nitrosoureas component Gliadel wafer Prior CNS radiotherapy Patients receive prior chemotherapy malignant glioma prior baseline evaluation patient currently treat chemotherapeutic agent Patients few 100,000 platelet per mm3 few 3,500 leukocyte per mm3 Liver function test great equal 2.5 time upper limit normal ( transaminase ( SGOT , SGPT ) , total bilirubin , alkaline phosphatase ) Serum creatinine equal great 1.5 time upper limit normal , blood urea nitrogen ( BUN ) equal great 2.5 time upper limit normal Pregnancy , lactate female female childbearing potential employ adequate contraception Participation investigational protocol prior twelve month type malignancy Psychological , familial , sociological geographical condition permit adequate medical followup compliance study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Brain Tumor</keyword>
	<keyword>GBM</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Giladel</keyword>
	<keyword>Temozolomide</keyword>
</DOC>